| ¿µ¹® | lung cancer | ÇÑ±Û | Æó¾Ï |
|---|---|---|---|
| ¼³¸í | ÇãÆÄ¿¡ »ý±â´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. °¡Àå ¿¹Èİ¡ ³ª»Û Á¾¾çÁßÀÇ Çϳª·Î½á Á¶±â¹ß°ßÀÌ ¾î·Æ°í Áõ¼¼ ¶ÇÇÑ ´Ê°Ô ³ªÅ¸³ª¼, ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£³ª Ä¡·áÈÄ¿¡µµ ´ë°³ 8%¸¸ÀÌ 5³â »ýÁ¸ÀÌ °¡´ÉÇÑ ¾Ç¼ºÁ¾¾çÀÌ´Ù. À¯¹ßÀÎÀڷδ ´ëÇ¥ÀûÀ¸·Î ´ã¹è°¡ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, À¯ÀüÀûÀÎ ¿ä¼Òµµ ¾î´À Á¤µµ ±â¿©ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. |
||
| ¿µ¹® | heart-lung machine | ÇÑ±Û | ½ÉÀå-ÇãÆÄ ±â°è |
|---|---|---|---|
| ¼³¸í | ½ÉÀåÀÇ ¼ö¼ú¿¡ »ç¿ëµÇ´Â ±â°è·Î¼ ½ÉÀåÀÌ ¼ö¼úÀ» ¹Þ°í ÀÖ´Â µ¿¾È ±â´ÉÀ» ÇÏÁö ¸øÇϹǷΠÀÌ ±â´ÉÀ» ´ë½Å ÇØÁÖ´Â ±â°èÀÌ´Ù. À̰ÍÀº ´ëÁ¤¸Æ°ú ´ëµ¿¸Æ»çÀÌ¿¡ ¿¬°áÀÌ µÇ¾î¼ Ç÷¾×À» °Á¦·Î ¼øÈ¯½ÃŰ¸é¼ ´ëÁ¤¸Æ¿¡¼ ¿Â ÇÇ¿¡ »ê¼Ò¸¦ °ø±ÞÇÏ¿© ´ëµ¿¸ÆÀ¸·Î µ¹·Á º¸³»´Â ¿ªÇÒÀ» ÇÑ´Ù. Áï ½ÉÀå°ú ÆóÀÇ ¿ªÇÒÀ» µ¿½Ã¿¡ ÇÏ´Â ±â°èÀÌ´Ù. |
||
| ¿µ¹® | total lung capacity | ÇÑ±Û | ÀüÆó¿ë·®, ¿ÂÇãÆÄ¿ë·® |
|---|---|---|---|
| ¼³¸í | ÆóȰ·®(°¡´ÉÇÑ ÇÑ ±í°Ô µé¿© ¸¶½Å ½ÃÁ¡ºÎÅÍ ÃµÃµÈ÷ ÇѲ¯ ³»½® ¿ë·®)¿¡ Àܱⷮ(ÃÖ´ë ³¯¼ûÀ§Ä¡¿¡¼ Æó³»¿¡ ³²Àº ¿ë·®. ¾à 1,200mL)À» ÇÕÇÑ °ÍÀÌ´Ù. °Ç°ÇÑ ¼ºÀÎÀº 6,000~7,000mL. Æó±âÁ¾, ¸¸¼º ±â°üÁö¿° µîÀÇ Æó»ö¼º Àå¾Ö·Î Áõ°¡ÇÏ°Ô µÇ´Â ÇÑÆí ÇãÆÄ¼¶À¯Áõ, ¹«±âÆó, Èä¼ö, Èä°ûº¯Çü µîÀÇ ±¸¼Ó¼º Àå¾Ö·Î °¨¼ÒÇÑ´Ù. |
||
| ¿µ¹® | ovarian cancer | ÇÑ±Û | ³¼Ò¾Ï |
|---|---|---|---|
| ¼³¸í | ¿©¼ºÀÇ ³¼Ò¿¡ ¹ß»ýÇÏ´Â ¾Ï. ºÎÀΰúÁ¾¾çÀ¸·Î¼ 50¼¼ ÀÌ»ó ¿©¼º¾Ç¼ºÁ¾¾çÀÇ ¾à 18%¸¦ Â÷ÁöÇÑ´Ù. Á¾¾çÀº ´ë°³ º¹ºÎ ±í¼÷È÷ À§Ä¡ÇϹǷΠÁ¾¾çÀÌ ¸¹ÀÌ ÁøÇàµÈ »óÅ¿¡¼ ¹ß°ßµÇ´Â ¼ö°¡ ¸¹À¸¸ç, ¶ÇÇÑ Á¾¾çÀÇ Ãʱ⿡´Â Áõ»óÀÌ °ÅÀÇ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ ´õ¿í Á¶±â¹ß°ßÀÌ ¾î·Æ´Ù. ¾ÆÁÖ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÌ ¹ß»ýÇϸç, ¿¹Èĵµ °¢±â ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù. ´ëÇ¥ÀûÀÎ ¾ÏÀ¸·Î À强³¶»ù¾ÏÁ¾(serous cystadenocarcinoma), Á¡¾×³¶»ù¾ÏÁ¾(mucinous cystadenocarcinoma), Á¾ÀÚ¼¼Æ÷Á¾(germinoma µîÀÌ ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû Ä¡·á°¡ ¼±ÇàµÇ¾î¾ß ÇÏÁö¸¸, ¸¹ÀÌ ÁøÇàµÇ¾î ÀÌ¹Ì ´Ù¸¥ Á¶Á÷À¸·Î ÀüÀ̰¡ ÀÌ·ç¾îÁø »óÅ¿¡¼´Â ÈÇпä¹ýÀÌ ¼±ÅÃÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | cancer | ÇÑ±Û | ¾Ï |
|---|---|---|---|
| ¼³¸í | ³¡¾øÀÌ ºÐ¿À» ÇÏ¿© Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇÏ¿© ´Ù¸¥ Àå±â¿¡±îÁö ÀüÆÄµÉ ¼ö ÀÖ´Â ¼¼Æ÷ÀÇ µ¢¾î¸®. Áï ¾Ç¼º ½Å»ý¹°À» ¸»ÇÑ´Ù. ½Å»ý¹°Àº ¾Ç¼º°ú ¾ç¼ºÀÌ Àִµ¥, ¾Ç¼ºÀÏ °æ¿ì¿¡´Â ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇØ¼ ¸Ö¸® ´Ù¸¥ ¶³¾îÁø Àå±â·Î ¾Ï¼¼Æ÷ÀÇ ÀüÆÄ°¡ °¡´ÉÇÏ¿© ´Ù¸¥ Àå±â¿¡µµ ¾ÏÀ» ÀüÀÌÇϸç, ¾ç¼ºÀº õõÈ÷ ÀÚ¶ó°í ´Ù¸¥°÷À¸·Î ÀüÀ̰¡ »ý±âÁö ¾Ê´Â´Ù. ¾ÏÀº ¾ÏÁ¾°ú À°Á¾ÀÇ µÎ °¡Áö·Î ³ª´ ¼ö°¡ ÀÖ´Ù. ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º½Å»ý¹°À» À̸£´Â ¸»À̰í À°Á¾À̶õ ºñ»óÇǼº¼¼Æ÷ ƯÈ÷ Áß°£¿±¼¼Æ÷(¹ß»ý´ç½Ã¿¡ Áß°£¿±¿¡ ÇØ´çÇÏ´Â Á¶Á÷À¸·Î ¹ß»ýÈÄ¿¡ Á¶Á÷»çÀÌ¿¡ ºÐÆ÷ÇÏ¸é¼ Á¶Á÷À» ÁöÁöÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °áÇÕÁ¶Á÷, Ç÷°ü, ¸²ÇÁ°ü µîÀÌ µÈ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º ½Å»ý¹°À» À̸£´Â ¸»ÀÌ´Ù. |
||
| CC | calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card... |
|---|---|
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| LC | Laennec cirrhosis; Langerhans cell; late clamped; large chromophobe; lecithin cholesterol acyltransf... |
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
| LC | Lung Cancer |
|---|---|
| LCSG | Lung Cancer Study Group |
| NSCLC | Non Small Cell Lung Cancer |
| SCLC | Small Cell Lung Cancer |
| ACTG | AIDS Clinical Trials Group |
| cancer, lung | Cancer of the major organ of respiration the lung. Lung cancer kills more men and women than any other form of cancer. Since the majority of lung cancer is diagnosed at a relatively late stage, only 10% of all lung cancer patients are ultimately cured. Eight out of 10 lung cancers are due to tobacco smoke. Lung cancers are classified as either small cell or non-small cell cancers. Persistent cough and bloody sputum can be symptoms of lung cancer. Lung cancer can be diagnosed based on examination of sputum, or tissue examination with biopsy using bronchoscopy, needle through the chest wall, or surgical excision. (12 Dec 1998) |
|---|---|
| metastatic cancer to the lung | The spread of cancerous tumours from a distant organ to the lung. Due to the lungs tremendous blood and lymphatic supply it is a frequent site for metastatic cancer. Cancers which commonly metastasize to the lung include osteosarcoma, breast cancer, neuroblastoma, Wilm's tumour and non-Hodgkin's lymphomas. (27 Sep 1997) |
| metastatic lung cancer | The spread of cancerous tumours from a distant organ to the lung. Due to the lungs tremendous blood and lymphatic supply it is a frequent site for metastatic cancer. Cancers which commonly metastasize to the lung include osteosarcoma, breast cancer, neuroblastoma, Wilm's tumour and non-Hodgkin's lymphomas. (27 Sep 1997) |
| secondary lung cancer | The spread of cancerous tumours from a distant organ to the lung. Due to the lungs tremendous blood and lymphatic supply it is a frequent site for metastatic cancer. Cancers which commonly metastasize to the lung include osteosarcoma, breast cancer, neuroblastoma, Wilm's tumour and non-Hodgkin's lymphomas. (27 Sep 1997) |
| small cell lung cancer | A type of lung cancer in which the cells are small and round. Also called oat cell lung cancer. (12 Dec 1998) |
| nonsmall cell lung cancer | A general classification for squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. (12 Dec 1998) |
| lung cancer | A cancerous growth in lung tissue. Lung cancer may be metastatic from another source (colon) or may be primary (tumour is of lung cell origin). Classification is based on the type of cell the lung cancer originates from (adenocarcinoma, alveolar cell carcinoma, squamous cell carcinoma, large cell and small cell carcinomas). (27 Sep 1997) |
| Addison's clinical planes | A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison. (05 Mar 2000) |
| pathology, clinical | A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids. (12 Dec 1998) |
| chemistry, clinical | The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy. (12 Dec 1998) |
| pharmacology, clinical | The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. (12 Dec 1998) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| Millon clinical multiaxial inventory | A paper and pencil test, consisting of 20 clinical scales derived from 175 self-descriptive statements, and developed in 1977 for use in the assessment of psychopathology and the more enduring patterns of personality; specifically designed to correspond with some of the disorders of personality included in the Diagnostic and Statistical Manual of Mental Disorders used in diagnosis by mental health professionals. Synonym: Millon clinical multiaxial inventory. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|